Nicotinic antagonists

Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results

Retrieved on: 
Friday, July 30, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, General anesthetics, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Therapy, Bipolar disorder, Mental health

Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry.

Key Points: 
  • Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry.
  • Braxia Health is the first to offer novel Ketamine therapy, including intravenous therapy, to patients in a private clinical setting in Quebec.
  • In June 2021, the Company announced that Chief Medical and Scientific Officer Dr. Joshua Rosenblat, will initiate a first-of-its-kind ketamine clinical trial to treat bipolar depression.
  • "Braxia Scientific has achieved significant milestones to date, and we are picking up the pace," noted CEO Dr. Roger McIntyre.

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, NMDA receptor antagonists, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Nutraceutical, Psychedelic drug

The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Key Points: 
  • The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.
  • Todays announcements are further evidence of the synergies between our growing clinic network and our contract research offerings, said Ketamine Ones Interim CEO, Adam Deffett.
  • We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One, added Mr. Deffett.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Sedatives, Ketamine, Neurocognition, IRPS

IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.

Key Points: 
  • IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.
  • NeuroCatch is expected to remain a key part of IRPs service offering as Ketamine One expands its network to new veteran-centric markets across Canada.
  • Unique service offerings such as NeuroCatch help Ketamine Ones clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time.
  • Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy.

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Patent

The Companys intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.

Key Points: 
  • The Companys intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.
  • I am pleased with our continued dedication to becoming a leader of novel ketamine products and implementing a patent strategy that would protect our clinical development and commercialization initiatives.
  • The patent application, entitled Methods and Compositions of Ketamine Formulation for Intradermal Administration, describes the potential improvement and therapeutic value of ketamine by delivering it through the skin.
  • PharmaTher is positioning itself as an innovator of novel uses, formulations and delivery forms of ketamine.

Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Drugs, Antidepressants, General anesthetics, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine

VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin further development.

Key Points: 
  • VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the Company) is excited to announce that its wholly owned subsidiary Akome Biotech Ltd. (Akome) has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin further development.
  • The formulation of Akomes breakthrough depression treatment, also known as AKO003, has now been developed and a provisional matter of composition patent application for AKO003 has been filed with the United States Patent and Trademark Office (USPTO) under application 63128302.
  • With the formula finalized the next step is the development of this drug to bring it closer to human trials and an eventual roll out to market.
  • Akomes psychedelic-based drug formulation for the treatment of depression will position Core One as a pioneer in the alternative depression treatment market, stated Joel Shacker, the Companys CEO.

Braxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada Clients

Retrieved on: 
Tuesday, July 20, 2021
Psychoactive drugs, Psychiatry, Drugs, Psychiatric diagnosis, Abnormal psychology, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Depression, Psilocybin, Major depressive disorder

Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Key Points: 
  • Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • Braxia develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
  • The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami

Retrieved on: 
Friday, July 9, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, Wellness, Tristar, Clinical trial

Tristar Wellness is an upscale Miami Beach Florida based medical facility with an experienced team of doctors focused on implementing the latest in medical technology and research.

Key Points: 
  • Tristar Wellness is an upscale Miami Beach Florida based medical facility with an experienced team of doctors focused on implementing the latest in medical technology and research.
  • Dane Jackman, Managing Director of Tristar Wellness, said, This partnership marks the first in a line of Ketamine related micro-trials slated at Tristar Wellness, Miami Beach.
  • Ehave Chief Executive Officer, Ben Kaplan, said, "Hiring an IRB is a very important step in our ketamine clinical Trials in Miami with Tristar Wellness.
  • The safety of the individuals participating in our trials is of utmost importance to both Ehave and Tristar Wellness.

Leading Psychedelic Wellness Company Delic Completes Acquisition of Ketamine Infusion Centers LLC, Adding Health Clinic Chain to Portfolio

Retrieved on: 
Tuesday, July 6, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Ketamine, OTC Markets Group, WellPet, Delić

VANCOUVER, BC, July 6, 2021 /PRNewswire/ -Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, July 6, 2021 /PRNewswire/ -Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketamine Infusion Centers LLC ("KIC").
  • KIC will be strategically positioned to leverage DELIC platform and brand: DELIC expects to drive patients to KIC through its media platform and become a national leader
    Established history of providing ketamine infusion services.
  • "The DELIC team is committed to making psychedelic wellness accessible to the masses and with this chain of clinics we are making that vision possible."
  • DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

Retrieved on: 
Tuesday, July 6, 2021
Post-traumatic stress disorder, Psychiatry, Psychology, Mind, Adverse childhood experiences, Anxiety disorders, Aftermath of war, Nicotinic antagonists, Clinician Administered PTSD Scale, Psychological trauma, BNC-210, Child PTSD Symptom Scale

The ATTUNE Study is a randomised, double-blind, placebo-controlled, multi-centre Phase 2b clinical trial with a 12-week treatment period.

Key Points: 
  • The ATTUNE Study is a randomised, double-blind, placebo-controlled, multi-centre Phase 2b clinical trial with a 12-week treatment period.
  • The primary objective is to compare BNC210 to placebo on the improvement in PTSD symptom severity as measured by the Clinician Administered PTSD scale for DSM-5 (CAPS-5) following 12 weeks of treatment.
  • An oral tablet formulationof BNC210, showing much improved absorption over the previous liquid suspension formulation, will be evaluated in this study.
  • BNC210 oral tablet formulation is currently being evaluated in a second Phase 2b trial for the treatment of Post-Traumatic Stress Disorder (PTSD) for which it was granted Fast Track designation by the FDA.

Ehave, Inc. To Be One Of Four Main Sponsors At The Third Annual Psytech Summit on July 19th and 20th, 2021

Retrieved on: 
Friday, July 2, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Clinical research, Chloroarenes, Nicotinic antagonists, Sedatives, Microdosing, Ketamine, Digital therapeutics

The third annual PsyTech Summit will cover the most heated topics in the psychedelic sector today, like ketamine-assisted therapy, microdosing, promising new innovations in developmental phases, and much more.

Key Points: 
  • The third annual PsyTech Summit will cover the most heated topics in the psychedelic sector today, like ketamine-assisted therapy, microdosing, promising new innovations in developmental phases, and much more.
  • Sponsoring the PsyTech Summit is a great opportunity for Ehave and its shareholders as we roll out our KetaDASH platform and home infusion service, said Ben Kaplan, CEO of Ehave.
  • The third annual Psytech Summit is produced by PsyTech Inc., a leading source of education, clinical care and clinical tools for the fast-growing psychedelic medical sector.
  • Speakers and moderators for the Third Annual Psytech Summit include:
    Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients.